Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib.…
$COGT https://t.co/bTFRWTn4KD
$COGT got pretty cheap! It bounced here couple times! https://t.co/er0MW8g9Nw
$KURA $MLYS $COGT $PRQR $NKTX getting cheap with those xbi dips.... ofc can get cheaper in this market so Slow DCA as usual!
13 analysts rate COGT Buy on consensus.
Consensus price target: $54.17 (+75.05% upside from $30.95)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Fairmount Funds Management LLC director | Mar 31, 2026 | Sale | 7,000,000 | $242.62M |
| Fairmount Funds Management LLC director | Jan 22, 2026 | Sale | 3,500,000 | $127.4M |
| Robinson John Edward Chief Scientific Officer | Dec 26, 2025 | Sale | 90,000 | $3.49M |
| Sachs Jessica Chief Medical Officer | Dec 26, 2025 | Sale | 82,642 | $3.2M |
| Green John L. Chief Financial Officer | Dec 26, 2025 | Sale | 77,000 | $2.98M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-328.94M |
| 2024 | $0 | — | $-255.86M |
| 2023 | $0 | — | $-192.41M |
Stock data for COGT: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics